RxDoctor Payments Data

Peter Tortora, MD

Internal Medicine · Fairfield, CTNPI 1235190984

Payments from drug & device makers

$17,332in general payments, 2019–2025

Across 902 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • GSK$2K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Merck$859
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$17,19799%
  • Education$1351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,332 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$67,122
Medicare patients
205
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$65,665
JardianceEmpagliflozin18$17,450
OzempicSemaglutide12$13,844
ProcritEpoetin Alfa13$11,873
TradjentaLinagliptin37$10,428
FarxigaDapagliflozin Propanediol19$6,010
Breo ElliptaFluticasone/Vilanterol12$4,429
SynthroidLevothyroxine Sodium35$2,634
Atorvastatin Calcium254$2,627
Amlodipine Besylate225$2,145
Levothyroxine Sodium181$1,996
Rosuvastatin Calcium175$1,969
Nebivolol Hcl16$1,501
Escitalopram Oxalate83$1,353
Pantoprazole Sodium70$1,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$766$65,66580 claims
Boehringer IngelheimJardiance, Tradjenta$1,377$27,87855 claims
Novo NordiskOzempic$556$13,84412 claims
Johnson & JohnsonProcrit$844$11,87313 claims
AstraZenecaFarxiga$2,037$6,01019 claims
GSKBreo Ellipta$1,717$4,42912 claims
AbbVieSynthroid$2,647$2,63435 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$120$1,996181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →